Overview

• Citron Research’s June 23 report drove Teladoc shares up more than 5%, as the firm argued the stock trades like a “coiled spring.”
• The $30 million April acquisition of UpLift adds virtual mental health therapy, psychiatry and medication management with insurance billing infrastructure.
• Executives project a 1% increase in BetterHelp conversion rates through insurance reimbursement could generate about $40 million in additional annual revenue.
• Chuck Divita, who became CEO in April, brings healthcare CFO experience and a tighter cost discipline to replace the company’s growth-obsessed former leadership.
• At under 1× EV/Sales and 6× free cash flow, Teladoc’s valuation is seen as deeply discounted, offering significant upside if its turnaround strategy succeeds.